Atrium Therapeutics Inc RNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Atrium Therapeutics to Participate in Upcoming Investor Conferences
-
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
-
Atrium Gets $15 Million in Latest Milestone Payment from Bristol Myers Squibb
-
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
-
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Trading Information
- Previous Close Price
- $8.14
- Day Range
- $7.68–8.42
- 52-Week Range
- $7.68–16.77
- Bid/Ask
- $7.77 / $8.06
- Shares Outstanding
- 17.11M
- Market Cap
- $134.11M
- Volume/Avg
- 533,805 / 250,616
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- —
Valuation
|
Metric
|
RNA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.63 |
Price/Sales | 3.75 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RNA
|
|---|---|
Quick Ratio | 8.38 |
Current Ratio | 8.73 |
Interest Coverage | — |
Quick Ratio
RNA
Profitability
|
Metric
|
RNA
|
|---|---|
Return on Assets (Normalized) | −26.68% |
Return on Equity (Normalized) | −34.67% |
Return on Invested Capital (Normalized) | −34.18% |
Return on Assets
RNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|PS&DJ! | LOCK|T>Jc$ | $128B | |||
| Moderna Inc
MRNA
| LOCK|>^%<q&Z | LOCK|&y | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!f%pWHy | LOCK|W$<%s | $76B | |||
| argenx SE ADR
ARGX
| LOCK|H#%>?z& | LOCK|<j | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|q^$R^c | LOCK|nK< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$@HwP% | LOCK|dDwRj | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hx&b<%P! | LOCK|@&?fn | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|^%@@y< | LOCK|&# | $24B | |||
| Incyte Corp
INCY
| LOCK|n&^Lr> | LOCK|JQY | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#x!#ncL | LOCK|m<r | $15B |
United States